Claims

1. A medicament for treating a solid tumor comprising a therapeutically effective amount of an adenovirus vector, wherein said vector comprises a polynucleotide which comprises a fas-chimera transgene transcriptionally linked to a pre-proendothelin promoter, wherein said therapeutically effective amount is 3×10^{12} to 1×10^{13} virus particles.

2. The medicament of claim 1, wherein said therapeutically effective amount is 3×10^{12} virus particles.

3. The medicament of claim 1, wherein said therapeutically effective amount is 1×10^{13} virus particles.

4. The medicament of claim 1, wherein said fas-chimera transgene comprises the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

5. The medicament of claim 1, wherein said pre-proendothelin promoter comprises the nucleotide sequence set forth in SEQ ID NO: 6 or the complementary sequence thereof.

6. The medicament of claim 1, wherein said pre-proendothelin promoter comprises the nucleotide sequence set forth in SEQ ID NO: 8 or the complementary sequence thereof.

7. The medicament of claim 1, wherein said pre-proendothelin promoter comprises the nucleotide sequence set forth in SEQ ID NO: 7 or the complementary sequence thereof.

8. The medicament of claim 1, wherein said pre-proendothelin promoter comprises the nucleotide sequence set forth in SEQ ID NO: 13 or the complementary sequence thereof.

9. The medicament of claim 1, wherein said pre-proendothelin promoter comprises the nucleotide sequence set forth in SEQ ID NO: 12 or the complementary sequence thereof.

10. The medicament of any one of claims 1-9, wherein said adenovirus vector is a non-replicating adenovirus vector.

11. The medicament of claim 10, wherein said non-replicating adenovirus vector is an adenovirus 5 vector.

12. The medicament of claim 1, wherein said adenovirus vector comprises the nucleic acid sequence set forth in SEQ ID NO: 9 or 10.

13. The medicament of any one of claims 1-9, wherein said solid tumor is a primary tumor.

14. The medicament of any one of claims 1-9, wherein said solid tumor is a metastatic tumor.

15. The medicament of any one of claims 1-9, wherein said solid tumor is a thyroid cancer.

16. The medicament of any one of claims 1-9, wherein said solid tumor is a neuroendocrine cancer.

17. The medicament of any one of claims 1-9, wherein said medicament is for systemic administration.

18. The method of claim 17, wherein said medicament is for administration by a route selected from the group consisting of intra-articular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, infusion, oral administration, rectal administration, nasal administration and inhalation.

19. The medicament of any one of claims 1-9, wherein said medicament is for administration in at least two separate systemic doses.

20. The medicament of any one of claims 1-9, wherein said medicament inhibits angiogenesis of said tumor.

21. The medicament of any one of claims 1-9, wherein said medicament inhibits growth of said tumor.

22. The medicament of any one of claims 1-9, wherein said medicament is for administration with a chemotherapeutic agent.

23. The medicament of claim 22, wherein said medicament is for administration after said chemotherapeutic agent.

24. The medicament of claim 22, wherein said medicament is for administration concomitantly or prior to said chemotherapeutic agent.

25. The medicament of claim 22, wherein said chemotherapeutic agent is doxorubicin, cisplatin, mitomycin C, 5-FU, capecitabine, leucovorin, irinotecan, oxaliplatin, temozolomide, folfox, dacarbazine, or docetaxel.

26. The medicament of claim 22, wherein said chemotherapeutic agent is sunitinib.

27. The medicament of claim 3, wherein said pre-proendothelin promoter comprises the nucleotide sequence set forth in SEQ ID NO: 6 or the complementary sequence thereof or the nucleotide sequence set forth in SEQ ID NO: 7 or the complementary sequence thereof.

28. The medicament of claim 27, wherein said fas-chimera transgene comprises the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

29. The medicament of claim 27 or 28 wherein said adenovirus vector is a non-replicating adenovirus 5 vector.